Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05833724 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma

Interventions

DRUG: Chidamide

Sponsor

Great Novel Therapeutics Biotech & Medicals Corporation